Bristol Myers Squibb Says FDA Accepts NDA For Mezigdomide In Combination With Carfilzomib And Dexamethasone In Patients With RRMM; PDUFA Date May 13, 2027

뉴스 본문을 불러오고 있어요.

Bristol Myers Squibb Says FDA Accepts NDA For Mezigdomide In Combination With Carfilzomib And Dexamethasone In Patients With RRMM; PDUFA Date May 13, 2027 | 웨이프 WAPE

Bristol Myers Squibb Says FDA Accepts NDA For Mezigdomide In Combination With Carfilzomib And Dexamethasone In Patients With RRMM; PDUFA Date May 13, 2027

기사 요약

관련 종목

댓글 —